FDA won't call for major Ketek label changes

12/14/2006 | Wall Street Journal, The · Reuters

Documents posted by the FDA ahead of today's FDA advisory committee meeting indicates the agency has no plans for big changes to the safety label of the Sanofi-Aventis antibiotic Ketek. A Sanofi spokeswoman says the company believes the drug's benefits outweigh risks for all of its approved uses.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA